Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QYHJ Granules versus Xeloda as second-line therapy for metastatic pancreatic cancer
ChiCTR-TRC-13003064Phase 2Completed
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Feb 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of Qingyi Huaji and capecitabine in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Overall survival. Started Feb 2013; status: completed.
02
Drugs
Qingyi Huajicapecitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR-TRC-13003064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-13003064.